EP2820048 - ANTIBODIES TO MATRIX METALLOPROTEINASE 9 [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 21.02.2020 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 15.03.2019 | ||
Former | Grant of patent is intended Status updated on 16.10.2018 | ||
Former | Examination is in progress Status updated on 30.07.2018 | ||
Former | Grant of patent is intended Status updated on 17.05.2018 | ||
Former | Examination is in progress Status updated on 18.11.2016 | Most recent event Tooltip | 08.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 10.08.2022 [2022/32] | Applicant(s) | For all designated states Gilead Biologics, Inc. 333 Lakeside Drive Foster City, CA 94404 / US | [2015/02] | Inventor(s) | 01 /
SMITH, Victoria 333 Lakeside Drive Foster City, CA 94404 / US | 02 /
MCCAULEY, Scott 660 Teresita Boulevard San Francisco, CA 94127 / US | [2015/02] | Representative(s) | Schnappauf, Georg, et al ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2019/16] |
Former [2015/02] | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 12708473.9 | 29.02.2012 | [2019/16] | WO2012US27160 | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013130078 | Date: | 06.09.2013 | Language: | EN | [2013/36] | Type: | A1 Application with search report | No.: | EP2820048 | Date: | 07.01.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.09.2013 takes the place of the publication of the European patent application. | [2015/02] | Type: | B1 Patent specification | No.: | EP2820048 | Date: | 17.04.2019 | Language: | EN | [2019/16] | Search report(s) | International search report - published on: | EP | 06.09.2013 | Classification | IPC: | C07K16/40, C12N9/64, G01N33/573, A61K39/00 | [2017/39] | CPC: |
C07K16/40 (EP,US);
A61P43/00 (EP);
C12N9/6491 (EP,US);
C12Y304/24035 (EP,US);
G01N33/573 (EP,US);
A61K2039/505 (EP,US);
A61K2039/54 (EP,US);
A61K2039/545 (EP,US);
C07K2317/24 (US);
C07K2317/34 (EP,US);
C07K2317/56 (EP,US);
C07K2317/565 (EP,US);
|
Former IPC [2015/02] | C07K16/40, C12N9/64, A61K39/395 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/02] | Extension states | BA | 26.09.2014 | ME | 26.09.2014 | Title | German: | ANTIKÖRPER GEGEN MATRIX-METALLOPROTEINASE-9 | [2015/02] | English: | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 | [2015/02] | French: | ANTICORPS DIRIGÉS CONTRE LA MÉTALLOPROTÉINASE 9 DE LA MATRICE | [2015/02] | Entry into regional phase | 26.09.2014 | National basic fee paid | 26.09.2014 | Designation fee(s) paid | 26.09.2014 | Examination fee paid | Examination procedure | 08.02.2013 | Request for preliminary examination filed International Preliminary Examining Authority: US | 26.09.2014 | Examination requested [2015/02] | 08.05.2015 | Amendment by applicant (claims and/or description) | 18.01.2016 | Despatch of a communication from the examining division (Time limit: M04) | 27.05.2016 | Reply to a communication from the examining division | 12.07.2016 | Despatch of a communication from the examining division (Time limit: M06) | 23.01.2017 | Reply to a communication from the examining division | 02.02.2017 | Despatch of a communication from the examining division (Time limit: M06) | 17.07.2017 | Reply to a communication from the examining division | 25.09.2017 | Despatch of a communication from the examining division (Time limit: M06) | 21.03.2018 | Reply to a communication from the examining division | 18.05.2018 | Communication of intention to grant the patent | 30.07.2018 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 02.08.2018 | Despatch of a communication from the examining division (Time limit: M02) | 12.09.2018 | Reply to a communication from the examining division | 17.10.2018 | Communication of intention to grant the patent | 13.02.2019 | Fee for grant paid | 13.02.2019 | Fee for publishing/printing paid | 13.02.2019 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 18.01.2016 | Opposition(s) | 20.01.2020 | No opposition filed within time limit [2020/13] | Fees paid | Renewal fee | 02.09.2014 | Renewal fee patent year 03 | 26.02.2015 | Renewal fee patent year 04 | 26.02.2016 | Renewal fee patent year 05 | 27.02.2017 | Renewal fee patent year 06 | 27.02.2018 | Renewal fee patent year 07 | 27.02.2019 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 29.02.2012 | AL | 17.04.2019 | AT | 17.04.2019 | CY | 17.04.2019 | CZ | 17.04.2019 | DK | 17.04.2019 | EE | 17.04.2019 | FI | 17.04.2019 | HR | 17.04.2019 | LT | 17.04.2019 | LV | 17.04.2019 | MC | 17.04.2019 | MK | 17.04.2019 | MT | 17.04.2019 | NL | 17.04.2019 | PL | 17.04.2019 | RO | 17.04.2019 | RS | 17.04.2019 | SE | 17.04.2019 | SI | 17.04.2019 | SK | 17.04.2019 | SM | 17.04.2019 | TR | 17.04.2019 | BG | 17.07.2019 | NO | 17.07.2019 | GR | 18.07.2019 | IS | 17.08.2019 | PT | 17.08.2019 | [2022/32] |
Former [2022/27] | HU | 29.02.2012 | |
AL | 17.04.2019 | ||
AT | 17.04.2019 | ||
CY | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
MC | 17.04.2019 | ||
MT | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SI | 17.04.2019 | ||
SK | 17.04.2019 | ||
SM | 17.04.2019 | ||
TR | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/49] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
MC | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SI | 17.04.2019 | ||
SK | 17.04.2019 | ||
SM | 17.04.2019 | ||
TR | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/26] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SI | 17.04.2019 | ||
SK | 17.04.2019 | ||
SM | 17.04.2019 | ||
TR | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/17] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SK | 17.04.2019 | ||
SM | 17.04.2019 | ||
TR | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/14] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SK | 17.04.2019 | ||
SM | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/11] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
EE | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
SK | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/10] | AL | 17.04.2019 | |
AT | 17.04.2019 | ||
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RO | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/09] | AL | 17.04.2019 | |
CZ | 17.04.2019 | ||
DK | 17.04.2019 | ||
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2020/04] | AL | 17.04.2019 | |
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
IS | 17.08.2019 | ||
PT | 17.08.2019 | ||
Former [2019/52] | AL | 17.04.2019 | |
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
PL | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
PT | 17.08.2019 | ||
Former [2019/51] | AL | 17.04.2019 | |
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
BG | 17.07.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
PT | 17.08.2019 | ||
Former [2019/50] | AL | 17.04.2019 | |
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
LV | 17.04.2019 | ||
NL | 17.04.2019 | ||
RS | 17.04.2019 | ||
SE | 17.04.2019 | ||
NO | 17.07.2019 | ||
GR | 18.07.2019 | ||
PT | 17.08.2019 | ||
Former [2019/49] | AL | 17.04.2019 | |
FI | 17.04.2019 | ||
HR | 17.04.2019 | ||
LT | 17.04.2019 | ||
NL | 17.04.2019 | ||
SE | 17.04.2019 | ||
NO | 17.07.2019 | ||
PT | 17.08.2019 | ||
Former [2019/48] | FI | 17.04.2019 | |
LT | 17.04.2019 | ||
NL | 17.04.2019 | ||
SE | 17.04.2019 | ||
NO | 17.07.2019 | ||
PT | 17.08.2019 | ||
Former [2019/47] | FI | 17.04.2019 | |
LT | 17.04.2019 | ||
NL | 17.04.2019 | ||
NO | 17.07.2019 | ||
Former [2019/44] | NL | 17.04.2019 | Cited in | International search | [A]WO0104157 (UNIV SOUTHERN CALIFORNIA [US]) [A] 1-41 * the whole document *; | [A]WO2004022096 (ALEXION PHARMA INC [US], et al) [A] 1-41 * the whole document *; | [XA]WO2007094842 (GENENTECH INC [US], et al) [X] 1,19,32 * the whole document * * in particular * * abstract * * figure 11A; sequence 413 * [A] 2-18,20-31,33-41; | [XA]WO2008154439 (IRM LLC, et al) [X] 3,19,32 * the whole document * * in particular * * abstract * * claim 4; sequence 59 * [A] 1,2,4-18,20-31,33-41; | [XI]WO2009111450 (DYAX CORP [US], et al) [X] 1,12,13,17-24,32,35-39 * the whole document * * in particular * * abstract * * page 1, line 14 - page 12, line 21 * * figures 1-10; examples 1-16; claims 1-53 * [I] 2-11,14-16,25-31,33,34,40,41; | [A]WO2009111508 (DYAX CORP [US], et al) [A] 1-41 * the whole document *; | [A]WO2010048432 (DYAX CORP [US], et al) [A] 1-41 * the whole document *; | [XA]WO2010059543 (MERCK SHARP & DOHME [US], et al) [X] 3,19,32 * the whole document * * in particular * * abstract * * page 239; sequence 250 * [A] 1,2,4-18,20-31,33-41; | [A]WO2011092700 (YEDA RES & DEV [IL], et al) [A] 1-41 * the whole document *; | [T]WO2012027721 (GILEAD BIOLOGICS INC [US], et al) [T] * the whole document *; | [Y] - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20031101), vol. 21, no. 11, doi:10.1016/J.TIBTECH.2003.08.007, ISSN 0167-7799, pages 484 - 490, XP004467495 [Y] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007 | [Y] - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (19960901), vol. 2, no. 3, doi:10.1016/S1380-2933(96)00045-0, ISSN 1380-2933, pages 169 - 179, XP004070292 [Y] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/S1380-2933(96)00045-0 | [A] - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, doi:10.1038/NRI1837, ISSN 1474-1733, pages 343 - 357, XP007901440 [A] 1-38 * the whole document * DOI: http://dx.doi.org/10.1038/nri1837 | [A] - WARK K L ET AL, "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (20060807), pages 657 - 670, (20060807), XP024892147 [A] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.addr.2006.01.025 | [A] - MARTENS ET AL, "A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains", BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, (20061229), vol. 1770, no. 2, doi:10.1016/J.BBAGEN.2006.10.012, ISSN 0304-4165, pages 178 - 186, XP005818408 [A] 1-41 * the whole document * DOI: http://dx.doi.org/10.1016/j.bbagen.2006.10.012 | [A] - JIALIANG HU ET AL, "Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody.", BIOCHEMICAL PHARMACOLOGY, (20040301), vol. 67, no. 5, ISSN 0006-2952, pages 1001 - 1009, XP055042352 [A] 1-41 * the whole document * DOI: http://dx.doi.org/10.1016/j.bcp.2003.10.030 | by applicant | US4816567 | EP0404097 | WO9311161 | US5391377 | US5545807 | US5545806 | US5569825 | US5625126 | US5633425 | US5661016 | - Methods in Enzymology, ACADEMIC PRESS | - HU ET AL., NATURE REVIEWS: DRUG DISCOVERY, (2007), vol. 6, pages 480 - 498 | - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410 | - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1977), vol. 25, pages 3389 - 3402 | - HIGGINS D. ET AL., NUCLEIC ACIDS RES, (1994), vol. 22, pages 4673 - 4680 | - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062 | - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315 | - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448 | - KABAT ET AL., J. BIOL. CHEM., (1977), vol. 252, pages 6609 - 6616 | - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917 | - MACCALLUM ET AL., J. MOL. BIOL., (1996), vol. 262, pages 732 - 745 | - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329 | - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596 | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536 | - HOOGENBOOM ET AL., J. MOL. BIOL, (1991), vol. 227, page 381 | - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581 | - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77 | - BOEMER ET AL., J. IMMUNOL., (1991), vol. 147, pages 86 - 95 | - MARKS ET AL., BIO/I'ECHNOLOGY, (1992), vol. 10, pages 779 - 783 | - LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859 | - MORRISON, NATURE, (1994), vol. 368, pages 812 - 813 | - FISHWALD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851 | - NEUBERGER, NATURE BIOTECHNOLOGY, (1996), vol. 14, page 826 | - LONBERG ET AL., INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93 | - ANGAL ET AL., MOLEC. IMMUNOL., (1993), vol. 30, pages 105 - 108 | - BAI, J. NEUROIMMUNOL., (1997), vol. 80, pages 65 - 75 | - WARREN, J. NEUROL. SCI., (1997), vol. 152, pages 31 - 38 | - TONEGAWA, J. EXP. MED., (1997), vol. 186, pages 505 - 515 | - FIX, PHARM RES., (1996), vol. 13, pages 1760 - 1764 | - SAMANEN, J. PHARM. PHARMACOL., (1996), vol. 48, pages 119 - 135 |